Inmune Bio, Inc. (INMB)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | - | 50,000 | - | - |
| Research and development | 5,804,000 | 7,639,000 | 10,067,000 | 7,053,000 |
| Impairment of acquired in-process research and development intangible assets | 16,514,000 | - | - | - |
| General and administrative | 2,253,000 | 2,316,000 | 2,219,000 | 2,812,000 |
| Total operating expenses | 24,571,000 | 9,955,000 | 12,286,000 | 9,865,000 |
| Loss from operations | -24,571,000 | -9,905,000 | -12,286,000 | -9,865,000 |
| Other income, net | 113,000 | - | 193,000 | - |
| Other income (expense), net | - | 166,000 | - | - |
| Other operating income (expense), net | - | - | - | 119,000 |
| Net loss | -24,458,000 | -9,739,000 | -12,093,000 | -9,746,000 |
| Other comprehensive income (loss) foreign currency translation | -153,000 | -35,000 | -323,000 | -44,000 |
| Total comprehensive loss | -24,611,000 | -9,774,000 | -12,416,000 | -9,790,000 |
| Net loss per common share basic (in dollars per share) | -1.05 | -0.43 | -0.6 | -0.5 |
| Net loss per common share diluted (in dollars per share) | -1.05 | -0.43 | -0.6 | -0.5 |
| Weighted average common shares outstanding basic (in shares) | 23,298,455 | 22,496,191 | 20,185,676 | 19,307,323 |
| Weighted average common shares outstanding diluted (in shares) | 23,298,455 | 22,496,191 | 20,185,676 | 19,307,323 |